Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase

Hepatitis C virus (HCV) infection or HCV-related liver diseases are now shown to cause more than 350,000 deaths every year. Adaptability of HCV genome to vary its composition and the existence of multiple strains makes it more difficult to combat the emergence of drug-resistant HCV infections. Among...

Full description

Bibliographic Details
Main Authors: Harikishore, Amaravadhi, Li, Enlin, Lee, Jia Jun, Cho, Nam-Joon, Yoon, Ho Sup
Other Authors: School of Biological Sciences
Format: Journal Article
Language:English
Published: 2015
Subjects:
Online Access:https://hdl.handle.net/10356/97886
http://hdl.handle.net/10220/38515
_version_ 1811685679412805632
author Harikishore, Amaravadhi
Li, Enlin
Lee, Jia Jun
Cho, Nam-Joon
Yoon, Ho Sup
author2 School of Biological Sciences
author_facet School of Biological Sciences
Harikishore, Amaravadhi
Li, Enlin
Lee, Jia Jun
Cho, Nam-Joon
Yoon, Ho Sup
author_sort Harikishore, Amaravadhi
collection NTU
description Hepatitis C virus (HCV) infection or HCV-related liver diseases are now shown to cause more than 350,000 deaths every year. Adaptability of HCV genome to vary its composition and the existence of multiple strains makes it more difficult to combat the emergence of drug-resistant HCV infections. Among the HCV polyprotein which has both the structural and non-structural regions, the non-structural protein NS5B RNA-dependent RNA polymerase (RdRP) mainly mediates the catalytic role of RNA replication in conjunction with its viral protein machinery as well as host chaperone proteins. Lack of such RNA-dependent RNA polymerase enzyme in host had made it an attractive and hotly pursued target for drug discovery efforts. Recent drug discovery efforts targeting HCV RdRP have seen success with FDA approval for sofosbuvir as a direct-acting antiviral against HCV infection. However, variations in drug-binding sites induce drug resistance, and therefore targeting allosteric sites could delay the emergence of drug resistance. In this study, we focussed on allosteric thumb site II of the non-structural protein NS5B RNA-dependent RNA polymerase and developed a five-feature pharmacophore hypothesis/model which estimated the experimental activity with a strong correlation of 0.971 & 0.944 for training and test sets, respectively. Further, the Güner-Henry score of 0.6 suggests that the model was able to discern the active and inactive compounds and enrich the true positives during a database search. In this study, database search and molecular docking results supported by experimental HCV viral replication inhibition assays suggested ligands with best fitness to the pharmacophore model dock to the key residues involved in thumbs site II, which inhibited the HCV 1b viral replication in sub-micro-molar range. HCV nonstructural protein NS5B RNA-dependent RNA polymerase (RdRP) mediates the catalytic role of viral RNA replication. Lack of host RNA-dependent RNA polymerase enzyme had made it an attractive and hotly pursued target for drug discovery efforts. In this study, we developed a five-feature pharmacophore (3D QSAR) model for thumb site inhibitors of HCV RdRP, which estimated the experimental activity with a strong correlation of 0.971 & 0.944 for training and test sets, respectively. Our database search and molecular docking results suggested that the compounds 1 and 2 with best fitness to the pharmacophore model were predicted to interact with key residues involved in thumbs site II and could inhibit the HCV RdRP activity. Further, the compounds 1 and 2 potently inhibited HCV 1b viral replication in sub-micro-molar range.
first_indexed 2024-10-01T04:48:21Z
format Journal Article
id ntu-10356/97886
institution Nanyang Technological University
language English
last_indexed 2024-10-01T04:48:21Z
publishDate 2015
record_format dspace
spelling ntu-10356/978862023-02-28T17:04:12Z Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase Harikishore, Amaravadhi Li, Enlin Lee, Jia Jun Cho, Nam-Joon Yoon, Ho Sup School of Biological Sciences DRNTU::Science::Biological sciences::Molecular biology Hepatitis C virus (HCV) infection or HCV-related liver diseases are now shown to cause more than 350,000 deaths every year. Adaptability of HCV genome to vary its composition and the existence of multiple strains makes it more difficult to combat the emergence of drug-resistant HCV infections. Among the HCV polyprotein which has both the structural and non-structural regions, the non-structural protein NS5B RNA-dependent RNA polymerase (RdRP) mainly mediates the catalytic role of RNA replication in conjunction with its viral protein machinery as well as host chaperone proteins. Lack of such RNA-dependent RNA polymerase enzyme in host had made it an attractive and hotly pursued target for drug discovery efforts. Recent drug discovery efforts targeting HCV RdRP have seen success with FDA approval for sofosbuvir as a direct-acting antiviral against HCV infection. However, variations in drug-binding sites induce drug resistance, and therefore targeting allosteric sites could delay the emergence of drug resistance. In this study, we focussed on allosteric thumb site II of the non-structural protein NS5B RNA-dependent RNA polymerase and developed a five-feature pharmacophore hypothesis/model which estimated the experimental activity with a strong correlation of 0.971 & 0.944 for training and test sets, respectively. Further, the Güner-Henry score of 0.6 suggests that the model was able to discern the active and inactive compounds and enrich the true positives during a database search. In this study, database search and molecular docking results supported by experimental HCV viral replication inhibition assays suggested ligands with best fitness to the pharmacophore model dock to the key residues involved in thumbs site II, which inhibited the HCV 1b viral replication in sub-micro-molar range. HCV nonstructural protein NS5B RNA-dependent RNA polymerase (RdRP) mediates the catalytic role of viral RNA replication. Lack of host RNA-dependent RNA polymerase enzyme had made it an attractive and hotly pursued target for drug discovery efforts. In this study, we developed a five-feature pharmacophore (3D QSAR) model for thumb site inhibitors of HCV RdRP, which estimated the experimental activity with a strong correlation of 0.971 & 0.944 for training and test sets, respectively. Our database search and molecular docking results suggested that the compounds 1 and 2 with best fitness to the pharmacophore model were predicted to interact with key residues involved in thumbs site II and could inhibit the HCV RdRP activity. Further, the compounds 1 and 2 potently inhibited HCV 1b viral replication in sub-micro-molar range. Accepted version 2015-08-25T06:43:38Z 2019-12-06T19:47:41Z 2015-08-25T06:43:38Z 2019-12-06T19:47:41Z 2015 2015 Journal Article Harikishore, A., Li, E., Lee, J. J., Cho, N.-J., & Yoon, H. S. (2015). Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase. Molecular Diversity, 19(3), 529-539. https://hdl.handle.net/10356/97886 http://hdl.handle.net/10220/38515 10.1007/s11030-015-9591-5 en Molecular diversity © 2015 Springer. This is the author created version of a work that has been peer reviewed and accepted for publication by Molecular Diversity, Springer. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1007/s11030-015-9591-5]. application/pdf
spellingShingle DRNTU::Science::Biological sciences::Molecular biology
Harikishore, Amaravadhi
Li, Enlin
Lee, Jia Jun
Cho, Nam-Joon
Yoon, Ho Sup
Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
title Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
title_full Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
title_fullStr Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
title_full_unstemmed Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
title_short Combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of HCV NS5B polymerase
title_sort combination of pharmacophore hypothesis and molecular docking to identify novel inhibitors of hcv ns5b polymerase
topic DRNTU::Science::Biological sciences::Molecular biology
url https://hdl.handle.net/10356/97886
http://hdl.handle.net/10220/38515
work_keys_str_mv AT harikishoreamaravadhi combinationofpharmacophorehypothesisandmoleculardockingtoidentifynovelinhibitorsofhcvns5bpolymerase
AT lienlin combinationofpharmacophorehypothesisandmoleculardockingtoidentifynovelinhibitorsofhcvns5bpolymerase
AT leejiajun combinationofpharmacophorehypothesisandmoleculardockingtoidentifynovelinhibitorsofhcvns5bpolymerase
AT chonamjoon combinationofpharmacophorehypothesisandmoleculardockingtoidentifynovelinhibitorsofhcvns5bpolymerase
AT yoonhosup combinationofpharmacophorehypothesisandmoleculardockingtoidentifynovelinhibitorsofhcvns5bpolymerase